Previous close | 11.46 |
Open | 11.57 |
Bid | 11.60 x 800 |
Ask | 11.65 x 600 |
Day's range | 11.29 - 11.64 |
52-week range | 5.71 - 16.99 |
Volume | |
Avg. volume | 805,512 |
Market cap | 888.692M |
Beta (5Y monthly) | 0.32 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Liquidia to feature two live posters sessions and five encore presentations covering its investigational products, YUTREPIA™ (treprostinil) inhalation powder and L606 (liposomal treprostinil) inhalation suspension MORRISVILLE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the company will present seven posters related to its product pipeline at the 7th World Symposia of Pulmonary Hypertension (WSPH) taking place June 29 to July 1, 2024, in Barcelona,
On May 31, Judge Andrews denied United Therapeutics’ motion for a preliminary injunction to block the launch of YUTREPIA in the PH-ILD indicationRuling reinforces the clear path for FDA to issue final decision on amended NDA for YUTREPIA to treat both PAH and PH-ILD MORRISVILLE, N.C., June 03, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that on May 31, Judge Andrews of the U.S. District Court for the District of Delaware (District Court) denied the motion for pre
MORRISVILLE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Michael Kaseta, chief operating officer and chief financial officer, will provide an update on the company's business during a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday June 5, 2024, beginning at 9:00 a.m. ET, in New York City, NY.Access to a webcast will be available to investors and other interested parties by accessing Liquidia’s website at https://l